Page 1334 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

61. Crawford SW, Clark JG. Bronchiolitis associated with bone 76. Ellis MJ, Parikh CR, Inrig JK, Kanbay M, Patel UD. Chronic
marrow transplantation. Clin Chest Med. 1993;14:741-749. kidney disease after hematopoietic cell transplantation: a sys-
62. Epler GR. Bronchiolitis obliterans organizing pneumonia. tematic review. Am J Transplant. 2008;8:2378-2390.
Semin Respir Infect. 1995;10:65-77. 77. Glezerman I, Jhaveri K, Watson T, et al. Chronic kidney dis-
63. Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer ease, thrombotic microangiopathy, and hypertension following
BE, Hackman RC. Association between acute and chronic graft- T cell-depleted hematopoietic stem cell transplantation. Biol
versus-host disease and bronchiolitis obliterans organizing Blood Marrow Transplant. 2010;16:976-984.
pneumonia in recipients of hematopoietic stem cell transplants. 78. Pasquini MC, Wang Z. Current use and outcome of hemato-
Blood. 2003;102:3822-3828. poietic stem cell transplantation. CIBMTR Summary Slides.
64. Ishii T, Manabe A, Ebihara Y, et al. Improvement in bronchiol- 2010. http://www.cibmtr.org/ReferenceCenter/SlidesReports/
itis obliterans organizing pneumonia in a child after allogeneic SummarySlides/Documents/SummarySlides_2010-S.pdf.
bone marrow transplantation by a combination of oral pred- 79. Faber-Langendoen K, Caplan AL, McGlave PB. Survival of
nisolone and low dose erythromycin. Bone Marrow Transplant. adult bone marrow transplant patients receiving mechanical
2000;26:907-910. ventilation: a case for restricted use. Bone Marrow Transplant.
65. Patriarca F, Skert C, Sperotto A, et al. Incidence, outcome, and 1993;12(5):501-507.
risk factors of late-onset noninfectious pulmonary complications 80. Rubenfeld GD, Crawford SW. Withdrawing life support from
after unrelated donor stem cell transplantation. Bone Marrow mechanically ventilated recipients of bone marrow trans-
Transplant. 2004;33:751-758. plants: a case for evidence-based guidelines. Ann Intern Med.
66. Rubbia-Brandt L. Sinusoidal obstruction syndrome. Clin Liver 1996;125(8):625-633.
Dis. 2010;14:651-668. 81. Khassawneh BY, White P Jr, Anaissie EJ, et al. Outcome from
67. Tay J, Tinmouth A, Fergusdon D, et al. Systematic review of mechanical ventilation after autologous peripheral blood stem
controlled clinical trials on the use of ursodeoxycholic acid for cell transplantation. Chest. 2002;121:185-188.
the prevention of hepatic veno-occlusive disease in hematopoi- 82. Soubani AO, Kseibi E, Bander JJ, et al. Outcome and prognostic
etic stem cell transplantation. Biol Blood Marrow Transplant. factors of hematopoietic stem cell transplantation recipients
2007;13(2):206-217. admitted to a medical ICU. Chest. 2004;126:1604-1611.
68. Richardson PG, Soiffer RJ, Antin JH, et al. Defibrotide for the 83. Afessa B, Tefferi A, Dunn WF, et al. Intensive care unit support
treatment of severe hepatic veno-occlusive disease and mul- and Acute Physiology and Chronic Health Evaluation III per-
tiorgan failure after stem cell transplantation: a multicenter, formance in hematopoietic stem cell transplant recipients. Crit
randomized, dose-finding trial. Biol Blood Marrow Transplant. Care Med. 2003;31:1715-1721.
2010;16:1005-1017. 84. Pene F, Aubron C, Azoulay E, et al. Outcome of critically ill
69. Richardson P, Linden E, Revta C, Ho V. Use of defibrotide in allogeneic hematopoietic stem-cell transplantation recipients:
the treatment and prevention of veno-occlusive disease. Expert a reappraisal of indications for organ failure supports. J Clin
Review of Hematology. 2009;2:365-376. Oncol. 2006;24:643-649.
70. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease 85. Huynh TN, Weigt SS, Belperio JA, et al. Outcome and prog-
after hematopoietic stem cell transplantation: update on defib- nostic indicators of patients with hematopoietic stem cell
rotide and other current investigational therapies. Bone Marrow transplants admitted to the ICU. J Transplant. 2009:917294.
Transplant. 2008;41:229-237. Epub. 2009 Sep 15.
71. Matsue K, Aoki T, Odawara J, et al. High risk of hepatitis B-virus 86. Moreno RP, Metnitz PG, Almeida E, et al. SAPS 3—from evalua-
reactivation after hematopoietic cell transplantation in hepati- tion of the patient to evaluation of the intensive care unit. Part 1:
tis B core antibody-positive patients. Eur J Hematol. 2009;83: objectives, methods and cohort description. Intensive Care Med.
357-364. 2005;31(10):1336-1344.
72. Mehta R, Kellum J, Shah S, et al. Acute Kidney Injury Network: 87. Zimmerman JE, Kramer AA, McNair DS, et al. Acute Physiology
report of an initiative to improve outcomes in acute kidney and Chronic Health Evaluation (APACHE) IV: hospital mortal-
injury. Critical Care. 2007;11:R31. ity assessment for today’s critically ill patients. Crit Care Med.
73. Bellomo R, Ronco C, Kellum J, Mehta R, Palevsky P. Acute 2006;34(5):1297-1310.
renal failure - definition, outcome measures, animal models, 88. Higgins TL, Teres D, Copes WS, et al. Assessing contemporary
fluid therapy and information technology needs: the Second intensive care unit outcome: an updated Mortality Probability
International Consensus Conference of the Acute Dialysis Admission Model (MPM0-III). Crit Care Med. 2007;35(3):827-835.
Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-R212. 89. Bokhari SW. Munir T, Memom S, et al. Impact of critical care
74. Liu H, Li YF, Liu BC, et al. A multicenter, retrospective study reconfiguration and track-and-trigger outreach team interven-
of acute kidney injury in adult patients with nonmyeloablative tion on outcomes of haematology patients requiring intensive
hematopoietic SCT. Bone Marrow Transplant. 2009;45:153-158. care admission. Ann Hematol. 2010;89:505-512.
75. Tokgoz B, Kocyigit I, Polat G, et al. Acute renal failure after
myeloablative allogeneic hematopoietic stem cell transplantation:
incidence, risk factors, and relationship with the quantity of
transplanted cells. Ren Fail. 2010;32:547-554.

Section07-O-ref.indd 3 1/21/2015 11:26:51 AM